Biohaven's Epilepsy Drug Deal: Up to $795M?

On August 26, Biohaven and SK Biopharmaceuticals announced a significant global licensing agreement concerning opakalim, Biohaven's primary epilepsy drug candidate. This collaboration is structured with potential payments reaching up to $795 million, supplemented by royalties on sales. SK Biopharmaceuticals has secured exclusive worldwide rights to Biohaven's Kv7 ion channel platform.

Biohaven will receive $400 million in near-term funding through this deal. The agreement includes $350 million at closing and an additional $50 million slated for 2027, alongside potential future milestone payments and tiered royalties on US net sales. SK Biopharmaceuticals will also assume ongoing costs associated with the Kv7 program, including certain obligations to Knopp Biosciences.

Evidence supporting opakalim's potential includes a proof-of-concept study where it significantly extended the time to a second generalized tonic-clonic seizure. In focal epilepsy patients, a substantial percentage experienced at least a 50% reduction in seizure frequency.

Opakalim is designed for once-daily administration without the need for titration, offering an advantage over existing treatments. Its partnership with SK Biopharmaceuticals, a company with a strong track record in epilepsy treatments, provides a clear commercialization pathway. The acquired capital will also support Biohaven's development of other pipeline assets, such as protein degraders BHV-1300 and BHV-1400.

While the deal provides crucial funding and streamlines development, Biohaven relinquishes full control of a potentially high-value asset. The royalty rates, though substantial, represent a fraction of outright ownership. Furthermore, existing claims from other parties on opakalim's future revenue are a factor in the overall financial structure.